Auto-HSCT induces sustained responses in severe systemic sclerosis patients failing pulse cyclophosphamide

Bone Marrow Transplantation

Volumn 47, Issue 11, 2012, Pages 1486-1487

  Moore, J ^a   Englert, H ^b   Furlong, T ^a   Poon, T ^a   Milliken, S ^a   Ma, D ^a  

^a ST VINCENT S HOSPITAL   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; THYMOCYTE ANTIBODY;

ADULT; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DOSE RESPONSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; FEMALE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LETTER; MALE; MODIFIED RODNAN SKIN SCORE; PATIENT SAFETY; PILOT STUDY; PRIORITY JOURNAL; RECURRENT DISEASE; SCORING SYSTEM; SYSTEMIC SCLEROSIS; VISUAL ANALOG SCALE;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; SCLERODERMA, SYSTEMIC; YOUNG ADULT;

EID: 84869096982     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2012.67     Document Type: Letter

References (10)

1. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683-1691. (Pubitemid 43728250)
2. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-2666.
3. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis 2010; 69: 1809-1815.
4. Bryan C, Knight C, Black CM, Silman AJ. Prediction of five-year survival following presentation with scleroderma-development of a simple model using three disease factors at first visit. Arthritis Rheum 1999; 42: 2660-2665. (Pubitemid 30327188)
5. Tyndall A, Gratwohl A. Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1997; 19: 643-645. (Pubitemid 27182485)
6. Farge D, Labopin M, Tyndall A, Fassas A, Mancardi GL, Van Laar J et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95: 284-292.
7. van Laar JM, Farge D, Tyndall A. Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis. Ann Rheum Dis 2005; 64: 1515. (Pubitemid 41623870)
8. Nash RA, McSweeney PA, Crofford LJ, Abidi M, Chen C-S, Godwin JD et al. Highdose immunosuppressive therapy and autologous hematopoietic cell transplantation for severe systemic sclerosis: long-term follow-up of the US multicenter pilot study. Blood 2007; 110: 1388-1396. (Pubitemid 47281441)
9. Snowden JA, Biggs JC, Milliken ST, Fuller A, Brooks PM. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. Arthritis Rheum 1999; 42: 2286-2292. (Pubitemid 30333407)
10. Burt RK, Shah SJ, Dill K, Grant T, Gheorghiade M, Schroeder J et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 2011; 378: 498-506.